Topics

MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2.

08:00 EDT 1st October 2019 | BioPortfolio

Summary of "MiR-605-3p inhibits malignant progression of prostate cancer by up-regulating EZH2."

This study aimed to investigate the effect of microRNA-605-3p (miR-605-3p) on cell proliferation, invasion and migration in prostate cancer cells, as well as its effects on the Enhancer Zeste Homolog 2 (EZH2) expression and the potential regulatory mechanisms.

Affiliation

Journal Details

This article was published in the following journal.

Name: European review for medical and pharmacological sciences
ISSN: 2284-0729
Pages: 8795-8805

Links

DeepDyve research library

PubMed Articles [20955 Associated PubMed Articles listed on BioPortfolio]

A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway.

Prostate cancer (PCa) is one of the most common cancers in males in China. Long noncoding RNAs (lncRNAs) reportedly play crucial roles in human cancer progression in many studies. However, the molecul...

MALAT1 knockdown inhibits prostate cancer progression by regulating miR-140/BIRC6 axis.

Prostate cancer (PCa) is the second most common cancer among men globally. Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 (MALAT1) has been reported to be implicated in tum...

Targeting POH1 inhibits prostate cancer cell growth and enhances the suppressive efficacy of androgen deprivation and docetaxel.

POH1, a member of the JAMM domain containing deubiquitinases, functions in malignant progression of certain types of cancer. However, the role of POH1 in prostate cancer (PCa) remains unclear.

METCAM/MUC18 is a new early diagnostic biomarker for the malignant potential of prostate cancer: Validation with Western blot method, enzyme-linked immunosorbent assay and lateral flow immunoassay.

METCAM/MUC18 expression was increased with the malignant progression of prostate cancer and also a bona fide metastatic gene, capable of initiating and driving the metastasis of a non-metastatic human...

Neural Transcription Factors in Disease Progression.

Progression to the malignant state is fundamentally dependent on transcriptional regulation in cancer cells. Optimum abundance of cell cycle proteins, angiogenesis factors, immune evasion markers, etc...

Clinical Trials [18228 Associated Clinical Trials listed on BioPortfolio]

Identify Genes/Pathways Responsible for Progression From Low Risk to Higher Risk Prostate Cancer

In Taiwan, about 70% of new incident prostate cancer patients have localized disease. Most patients were detected by PSA screening. Among them, many had low-risk PC, which is very likely l...

Ketogenic Diet and Prostate Cancer Surveillance Pilot

Men with indolent forms of prostate cancer are managed expectantly using active surveillance, with a goal of delaying treatment and its deleterious side effects. However, almost 50% of men...

Docetaxel and Diethylstilbestrol in the Treatment of Androgen Independent Prostate Cancer

This study is for men who have prostate cancer that has spread outside of the prostate gland and is no longer responding to hormone removal therapy. This study is designed to determine if...

Analysis of Prostate Cancer Short-Term Cultures Using Molecular Cytogenetic Methods

This study will examine prostate tumor tissue cultures to try to identify genetic abnormalities that contribute to the cause or progression of the disease. Patients with prostate cancer e...

Phase II Clinical Trial of Purified Isoflavones in Prostate Cancer: Comparing Safety, Effectiveness

The purpose of our study is to recruit and treat 260 men diagnosed with prostate cancer and scheduled for a prostatectomy with a capsule form of either purified isoflavones or placebo for ...

Medical and Biotech [MESH] Definitions

A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.

A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.

Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).

Quick Search


DeepDyve research library

Relevant Topics

Prostate Cancer
Prostate cancer (cancer de prostata) Prostate cancer (cancer de prostata) is a form of cancer that develops in the prostate, a gland in the male reproductive system. Most prostate cancers are slow growing; however, there are cases of aggressive prostat...

MicroRNAs (miRNAs)
A microRNA (abbreviated miRNA) is a small non-coding RNA molecule (containing about 22 nucleotides) found in plants, animals, and some viruses.  Key findings: miRNA is involved in the normal functioning of eukaryotic cells, so has dysregulation...


Searches Linking to this Article